Genocea Biosciences, Inc. GNCAQ
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Net Income | -37.19M | -33.20M | -34.90M | -- | -- |
| Total Depreciation and Amortization | 876.00K | 857.00K | 820.00K | -- | -- |
| Total Amortization of Deferred Charges | 700.00K | 700.00K | 600.00K | -- | -- |
| Total Other Non-Cash Items | -14.86M | -15.90M | -13.05M | -- | -- |
| Change in Net Operating Assets | 2.28M | 2.17M | 2.63M | -- | -- |
| Cash from Operations | -48.19M | -45.37M | -43.91M | -- | -- |
| Capital Expenditure | -3.14M | -3.29M | -3.72M | -- | -- |
| Sale of Property, Plant, and Equipment | 37.00K | 80.00K | 69.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3.10M | -3.21M | -3.66M | -- | -- |
| Total Debt Issued | 0.00 | 10.00M | 10.00M | -- | -- |
| Total Debt Repaid | -2.50M | -15.23M | -14.01M | -- | -- |
| Issuance of Common Stock | 7.89M | 11.57M | 13.23M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -377.00K | -377.00K | -- | -- |
| Cash from Financing | 5.39M | 5.96M | 8.85M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.90M | -42.62M | -38.72M | -- | -- |